中芯國際上半年淨利潤52.41億元 同比增長278.1%
中芯國際(00981.HK):上半年營收爲160.9億元,上半年淨利52.41億元,同比增長278.1%。上半年基本每股收益1元,上半年淨利潤50.1億元。上半年稀釋每股收益0.66元,去年同期0.25元。研發投入佔營業收入的比例爲12%,同比減少5.3%。
營業收入的增長主要是由於本期內銷售晶圓的數量及平均售價上升所致。銷售晶圓的數量由上年同期的2.8百萬片約當8英寸晶圓增加16.2%至本期內的3.3百萬片約當8英寸晶圓。平均售價(銷售晶圓收入除以總銷售晶圓數量)由上年同期4,143元增加至本期的4,390元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.